4.7 Article

mGlu2 mechanism-based interventions to treat alcohol relapse

期刊

FRONTIERS IN PHARMACOLOGY
卷 13, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2022.985954

关键词

alcohol addiction; craving; relapse; tolerance; DSM-based rat model; metabotropic glutamate receptors; positive allosteric modulators

资金

  1. Ministry of Education and Research Baden-Wuerttemberg
  2. Bundesministerium fuer Bildung und Forschung (BMBF) - SysMedSUDs consortium
  3. AhEAD consortium [01ZX1909A]
  4. ERA-NET consortium Psi-Alc [01KC2004A]
  5. Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [01EW1908]
  6. [TRR265/A05]

向作者/读者索取更多资源

A deficiency in mGlu2 function is identified as a common pathological mechanism underlying alcohol-seeking and relapse behavior. The use of mGlu2/3 agonists and mGlu2 PAMs effectively reduces relapse-like behavior. These drugs may be a potential treatment option for alcohol-dependent patients.
Recently we identified a deficiency in metabotropic glutamate receptor 2 (mGlu2) function in the corticoaccumbal pathway, as a common pathological mechanism underlying alcohol-seeking and relapse behavior. Based on this mechanism, we hypothesized that mGlu2/3 agonists and mGlu2 positive allosteric modulators (PAMs) may be effective in reducing relapse-like behavior. Two mGlu2/3 agonists, LY379268 and LY354740 (a structural analog of LY379268 six-fold more potent in activating mGlu2 over mGluR3), were tested in a well-established rat model of relapse, the alcohol deprivation effect (ADE) with repeated deprivation phases. Since these agonists do not readily discriminate between contributions of mGlu2 and mGluR3, we also tested LY487379, a highly specific PAM that potentiates the effect of glutamate on the mGlu2 with less specificity on other mGlu receptor subtypes. Both LY379268 and LY354740 significantly and dose-dependently reduced the expression of the ADE. No significant changes in water intake, body weight and locomotor activity were observed. Importantly, repeated administration of mGlu2/3 agonist did not lead to tolerance development. mGlu2 PAM LY487379 treatment significantly reduced expression of the ADE in both male and female rats. Combination treatment of mGlu2/3 agonist and PAM had similar effect on relapse-like drinking to that seen in mGlu2/3 agonist treatment alone. Together with other preclinical data showing that PAMs can reduce alcohol-seeking behavior we conclude that mGlu2 PAMs should be considered for clinical trials in alcohol-dependent patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据